CHU Ambroise Paré — Mons

Public research footprint of CHU Ambroise Paré, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET… · Breast Cancer · Metastatic Pancreatic Ductal Adenocarcinoma · Carcinoma, Renal Cell

Recently updated registry entries

NCT05970224 — A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact… (Completed)
NCT01564056 — Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women… (Completed)
NCT02864992 — Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at CHU Ambroise Paré?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.